Navigation Links
DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
Date:11/22/2013

dule, we expect to soon be delivering higher doses of VAL-083 and doing so more often."

Mr. Bacha added, "Although accelerating dose escalation is not expected to significantly alter the duration of the trial, we will treat fewer patients at sub-optimal doses and reach doses more likely to achieve meaningful patient benefit in a more cost efficient manner.  Importantly, we are proceeding on track to complete dose escalation and advance VAL-083 toward registration directed trials in refractory glioblastoma in the first half of 2014."

About VAL-083VAL-083 represents a first-in-class, small-molecule chemotherapeutic with a unique mechanism of action.  In more than 40 Phase 1 and Phase 2 clinical studies sponsored by the National Cancer Institute (NCI), VAL-083 has shown safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia.  VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.  As a potential treatment for glioblastoma, VAL-083's mechanism of action is unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar (temozolomide).  DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme patients. 

About Glioblastoma Multiforme (GBM)Glioblastoma multiforme (GBM) is the most common and most malignant form of brain cancer. Approximately 15,000 people are diagnosed with glioblastoma each year in the U.S., with similar incidence in Europe. Standard of care is surgery, followed by radiation therapy or combined radiation therapy and chemotherapy with temozolomide.  Approximately 60 percent of GBM patients treated with temoz
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
2. DelMar Pharmaceuticals Gives Quarterly Shareholder Update
3. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
4. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
5. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
6. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
7. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
9. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
10. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
11. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... SEATTLE und TÜBINGEN, Deutschland, 5. ... Melinda Gates Stiftung und das deutsche biopharmazeutische ... Stiftung 46 Millionen Euro (52 Millionen US-Dollar) ... im Bereich der medizinisch angewandten Messenger-RNA (mRNA). ... neue Ansätze zur Behandlung von Krankheiten und ...
(Date:3/5/2015)... 5, 2015  As the pharmaceutical industry works ... & Compliance professionals are placing a significant emphasis ... issued today by LRN, the leader in Ethics ... majority of respondents expressed that clarity on company ... of E&C training programs (57%), trumping understanding of ...
(Date:3/5/2015)... , March 5, 2015 Bayer HealthCare announced ... the Conquer Cancer Foundation of the American Society of ... health information technology platform designed to unlock vast quantities ... cancer.  "Bayer is proud to join ... to leverage Big Data to help people whose lives ...
Breaking Medicine Technology:Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3
... Sangart, Inc., a global biopharmaceutical company dedicated to ... perfusion and oxygenation of ischemic (oxygen deprived) tissues ... announced that its investigational biopharmaceutical product, MP4CO, has ... Food and Drug Administration (FDA) for use in ...
... health record (EHR) safety reporting system was announced today ... medical society and professional liability carrier executives in collaboration ... establishes a national system where physicians and other health ... and use of EHRs. Using a ...
Cached Medicine Technology:Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease 2Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease 3New National Electronic Health Record Safety System Launched 2New National Electronic Health Record Safety System Launched 3New National Electronic Health Record Safety System Launched 4New National Electronic Health Record Safety System Launched 5New National Electronic Health Record Safety System Launched 6
(Date:3/5/2015)... In honor of National Drug Facts ... drug and alcohol abuse in schools and communities across ... with information on some of the dangers and statistics ... National Institute on Drug Abuse, this annual promotion of ... the illusions that teens and young adults get from ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... the natural products coffee drinks category[1], today unveils its ... West in Anaheim, Calif. Concentrated Cold Brew (CCB) ... Café, which democratizes the next wave of the coffee-taste ... need to become their own baristas. , Califia ...
(Date:3/5/2015)... York, NY (PRWEB) March 05, 2015 ... orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named by ... the New York Metro area. Dr. Glashow has been ... its authoritative guide to the top specialty care doctors ... , The prestigious Castle Connolly program, which carefully screens ...
(Date:3/5/2015)... Nutrition Leaders, a premier purveyor of health, diet, ... Millennium 500 Creatine to its customers. Available from the ... creatine supplement that has been micronized to more quickly ... overall strength gains in users. , Creatine is a ... source in the body and helps fuel muscle contractions ...
(Date:3/5/2015)... 05, 2015 Wimbledon Health Partners ... vascular, echocardiogram and NCV testing, announced the ... Chief Medical Officer. Dr. Artel will be responsible for ... the WimbledonMED program and the continued growth and support ... working with Wimbledon Health Partners as a consulting physician ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3
... in a Queen,s University-led study do not have an influenza ... tested. In addition, key players were not involved in developing ... not good enough just to have a plan, you have ... will work in an emergency," says Dick Zoutman, Queen,s professor ...
... , AKRON, Ohio , Feb. 10 ... is launching its first bachelor,s degree programs in its 40-year ... Administration with a Business Management concentration Bachelor of Science ... Information Management Bachelor of Science – Technology Management with ...
... or GAD, have abnormalities in the way their brain unconsciously ... School of Medicine study, and the study authors say the ... our understanding of how emotion is regulated in everyday life. ... American Journal of Psychiatry. According to the National ...
... ... celiac disease, one of the most common and under-diagnosed autoimmune diseases, it,s symptoms, and how ... a year, one being day-time Emmy Award winner, Elisabeth Hasselbeck of ABC’s “The View”. ... (PRWEB) February 11, 2010 -- ...
... removal of tumors, study found , WEDNESDAY, Feb. 10 (HealthDay ... levels of spiritual thinking and feeling in patients, a finding ... and the physical makeup of the mind, researchers say. , ... Neuron , are based on research in patients who had ...
... , , PUYALLUP, Wash. , ... IT stimulus and the American Recovery and Reinvestment Act ... comprehensive digital imaging and data management integration project with ... paying dividends for MINW patients even after the completion ...
Cached Medicine News:Health News:Akron Institute of Herzing University Launches Its First Bachelor's Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT 2Health News:Akron Institute of Herzing University Launches Its First Bachelor's Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT 3Health News:People with anxiety disorder less able to regulate response to negative emotions, study shows 2Health News:People with anxiety disorder less able to regulate response to negative emotions, study shows 3Health News:Multi-Award Winning Author Tina Turbin Interviews Special Guest Dr. Peter H.R. Green, M.D. On The Thrive in Balance Radio Show 2Health News:Physical Changes in Brain Linked to Altered Spirituality 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 3
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: